Figure 8: Combination therapy with digoxin also improves outcomes in mice xenografted with BRAFV600E melanomas or NRAS driven human AML cells.
From: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
(a) NSG mice xenografted with four different BRAF mutant melanomas were treated with digoxin (10 mg kg−1 body mass per day) and/or BRAF inhibitor (dabrafenib; 20 mg kg−1 body mass per day) and/or MEK inhibitor (0.5 mg kg−1 body mass per day) (n=4–5 mice per treatment per melanoma; each melanoma was tested in an independent experiment). (b–e) Survival of NSG mice transplanted with HL60 (b,c) or U937 (d,e) human AML cells (n=5–12 mice per treatment). (b,d) Disease burden was measured by bioluminescence imaging. Data in a,b,d represent mean±s.d. Statistical significance was assessed by extra-sum-of-squares F tests (a,d) or by log-rank tests (c,e) followed by Bonferroni’s multiple comparison’s tests or a two-way analysis of variance followed by Dunnett’s multiple comparisons test (b). Each treatment compared with control (NS: not significant; *P<0.05; **P<0.01; ***P<0.001) or the combination compared with MEK inhibitor alone (#P<0.05; ##P<0.01;) or digitoxin alone (†P<0.05; ††P<0.01; †††P<0.001).
